A practical reference on counter-ion: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-17. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
At temperatures above 350 °C (662 °F), cellulose undergoes thermolysis (also called 'pyrolysis'), decomposing into solid char, vapors, aerosols, and gases such as carbon dioxide. Maximum yield of vapors which condense to a liquid called bio-oil is obtained at 500 °C (932 °F). Semi-crystalline cellulose polymers react at pyrolysis temperatures (350–600 °C (662–1,112 °F)) in a few seconds; this transformation has been shown to occur via a solid-to-liquid-to-vapor transition, with the liquid (called intermediate liquid cellulose or molten cellulose) existing for only a fraction of a second. Glycosidic bond cleavage produces short cellulose chains of two-to-seven monomers comprising the melt. Vapor bubbling of intermediate liquid cellulose produces aerosols, which consist of short chain anhydro-oligomers derived from the melt. Continuing decomposition of molten cellulose produces volatile compounds including levoglucosan, furans, pyrans, light oxygenates, and gases via primary reactions. Within thick cellulose samples, volatile compounds such as levoglucosan undergo 'secondary reactions' to volatile products including pyrans and light oxygenates such as glycolaldehyde.
== In biology == The best-studied 2-Carboxy-D-arabinitol-1-phosphate phosphatase is the enzyme that inactivates the RuBisCO inhibitor 2-carboxy-D-arabinitol-1-phosphate (CA1P). When light levels are high, the inactivation occurs after CA1P has been released from RuBisCO by RuBisCO activase. As CA1P is present in many but not all plants, CA1P-mediated regulation of RuBisCO is not universal for all photosynthetic life. Amino acid sequences of the CA1Pase enzymes from wheat, French bean, tobacco, and Arabidopsis thaliana reveal that the enzymes contain 2 different domains, indicating that it is a multifunctional enzyme. CA1Pase enzyme activity varies between different species due to their regulation by different redox-active compounds, such as glutathione. However, it is yet to be determined whether this process occurs in vivo. Wheat CA1Pase heterologously expressed in E. coli is also able to dephosphorylate the RuBisCO inhibitor D-glycero-2,3-diulose-1,5-bisphosphate.
BIA Separations was formed in 1998 by a group of scientists in Ljubljana, Slovenia to commercialize a new chromatographic resin based on monolith technology. Monolithic resin was developed independently by three different laboratories in late 1980s led by Hjertén, Švec and Tennikova. The company was one of the few Slovenian companies to receive venture capital funding at that time-Horizonte Venture Management realizing the potential of monoliths made the initial investment in the company. During that year, BIA Separations released its first commercial product marketed under the trade name of CIM (Convective Interaction Media). The new technique was named HPMC (High Performance Monolith Chromatography). During the 1999 and 2000s, the company promoted this new platform technology to the scientific and business community and registered several patents. In 2007 the company headquarters moved to Villach, Austria. In 2011 BIA Separations entered a strategic partnership with Japan Synthetic Rubber Corporation, a Japanese company producing synthetic materials. A strategic partnership agreement with Showa Denko K.K. (SDK) was signed in 2012.
== Design precautions == If sufficient reactivity control authority is available, the reactor can be restarted, but a xenon burn-out transient must be carefully managed. As the control rods are extracted and criticality is reached, neutron flux increases many orders of magnitude and the 135Xe begins to absorb neutrons and be transmuted to 136Xe. The reactor burns off the nuclear poison. As this happens, the reactivity increases and the control rods must be gradually re-inserted or reactor power will increase. The time constant for this burn-off transient depends on the reactor design, power level history of the reactor for the past several days (therefore the 135Xe and 135I concentrations present), and the new power setting. For a typical step up from 50% power to 100% power, 135Xe concentration falls for about 3 hours. The first time 135Xe poisoning of a nuclear reactor occurred was on September 28, 1944, in Pile 100-B at the Hanford Site. The B Reactor was a plutonium production reactor built by DuPont as part of the Manhattan Project. The reactor was started on September 27, 1944, but the power dropped unexpectedly shortly after, leading to a complete shutdown on the evening of September 28. Next morning the reaction restarted by itself. The physicists John Archibald Wheeler, working for DuPont at the time, and Enrico Fermi were able to identify that the drop in the neutron flux and the consequent shutdown was caused by the accumulation of 135Xe in the reactor fuel.
Sources: en.wikipedia.org
[W]ould it be too bold to imagine, that in the great length of time, since the earth began to exist, perhaps millions of ages before the commencement of the history of mankind, would it be too bold to imagine, that all warm-blooded animals have arisen from one living filament, which the great First Cause endued with animality, with the power of acquiring new parts attended with new propensities, directed by irritations, sensations, volitions, and associations; and thus possessing the faculty of continuing to improve by its own inherent activity, and of delivering down those improvements by generation to its posterity, world without end? Charles Darwin's views about common descent, as expressed in On the Origin of Species, were that it was probable that there was only one progenitor for all life forms:
=== Solution === The key to solving these equations in real devices is whenever possible to select regions in which most of the mechanisms are negligible so that the equations reduce to a much simpler form.
The tonic FSH and LH pulses sufficiently stimulate the theca cells of the follicle to produce androgen substrates for granulosa cell aromatase and induces cytochrome P450 enzymes that can produce progesterone later in the luteal phase. Androgen substrates from the theca cells are used by the enlarging granulosa cells to produce more estradiol. At mid-follicular phase, GnSAF bioactivity gradually declines as the dominant follicle is established and the small subordinate follicles undergo atresia. The development of the dominant follicle and regression of small non-dominant follicles is supported by increasing estradiol secretion. Towards the end of the follicular phase, GnSAF bioactivity is at its lowest due to the absence of small antral follicles. Estradiol secretion from the dominant follicle exponentially increases and exceeds a threshold which switches estradiol feedback on GnRH pulse frequency from negative to positive. Pituitary sensitivity to GnRH is restored.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.